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Background: Dietary fibers are associated with enhanced satiety. However, the mechanism of different dietary
fibers contributing to satiety-related gastrointestinal (GI) peptide release, especially in an obese population, is still
poorly understood. Polydextrose (PDX), a water-soluble glucose polymer, has demonstrated its ability to reduce
energy intake at a subsequent meal, but its mechanism of action requires further research. Also, there is limited
evidence on its capacity to regulate subjective feelings of appetite. This study examines the effects of PDX on
postprandial secretion of satiety-related GI peptides, short chain fatty acids (SCFAs), lactic acid, and subjective
appetite ratings in obese participants.
Methods: 18 non-diabetic, obese participants (42.0 y, 33.6 kg/m2) consumed a high-fat meal (4293 kJ, 36% from fat)
with or without PDX (15 g) in an acute, multicenter, randomized, double-blind, placebo-controlled and crossover
trial. Postprandial plasma concentrations of satiety-related peptides, namely ghrelin, cholecystokinin (CCK),
glucagon-like peptide 1 (GLP-1), and peptide YY (PYY), as well as SCFAs and lactic acid were assessed. GI peptide,
SCFA and lactate concentrations were then modeled using a linear mixed-effects model.
The subjective feelings of hunger, satisfaction, and desire to eat were evaluated using visual analogue scales (VAS),
which were analyzed as incremental areas under the curve (iAUC) during the satiation and satiety periods.
Results: We found that PDX supplementation increased plasma GLP-1 levels more than the placebo treatment
(P = 0.02). In the whole group, GLP-1 concentrations found in participants older than 40 years old were significantly
lower (P = 0.01) as compared to those aged 40 years or less. There were no statistically significant differences in
postprandial ghrelin, CCK, or PYY responses. The lactic acid concentrations were significantly (P = 0.01) decreased in
the PDX group, while no significant changes in SCFAs were found. PDX reduced iAUC for hunger by 40% (P = 0.03)
and marginally increased satisfaction by 22.5% (P = 0.08) during the post-meal satiety period.
Conclusion: Polydextrose increased the postprandial secretion of the satiety hormone GLP-1 and reduced hunger
after a high-fat meal. PDX also reduced the elevated postprandial lactic acid levels in plasma. Therefore, PDX may
offer an additional means to regulate inter-meal satiety and improve postprandial metabolism in obese participants.
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Obesity is characterized by a chronic, low-grade inflam-
mation that increases the prevalence of type 2 diabetes
(T2D), metabolic syndrome, hypertension and cardiovas-
cular disease [1,2]. Adipokines released from the in-
flamed adipose tissue can cause insulin resistance and
endothelial dysfunction [3]. An important link between
obesity, metabolic syndrome and dyslipidemia appears to
be the impaired ability of insulin to regulate glucose
utilization in peripheral tissues [4].
Obesity is also known to affect postprandial metabolic
processes and several implications of this effect have
been reviewed recently [4-6]. Many obesity-associated
metabolic risk factors, such as lipid abnormalities, may
in fact be associated with the pro-inflammatory state ini-
tiated within the adipose tissue. Interestingly, changes in
the concentrations of volatile short chain fatty acids
(SCFAs) have been noted in obese subjects. In addition,
the concentration of lactate seems to positively correlate
with body weight [7] and the production of lactate in adi-
pose tissue increases with the occurrence of obesity [7,8].
Satiation and satiety are processes that are involved
with the body’s appetite control system. Satiation leads
to the termination of eating and it is accompanied by
satisfaction of appetite. Satiety is explained as the feeling
of fullness, which hinders hunger and further consump-
tion of food. Satiation and satiety are both involved with
limiting energy intake and thus it is important for deter-
mining the total energy intake. [9] Satiation and satiety
are both influenced by energy density, macronutrient
composition, physical structure and the sensory quality
of ingested food [10]. If these two indicators of the sub-
jective feelings of appetite could be regulated to the
point where the intake of energy is significantly reduced,
this would eventually lead to the overall control of body
weight. In obese individuals, the ability of the gut to pre-
cisely monitor the luminal contents or relay this infor-
mation back to the central nervous system is hindered
[11]. An example is where the response of the vagal af-
ferent neurons to the presence of gut peptides deterio-
rates, therefore diminishing its normal ability to inhibit
food intake [11,12].
Gastrointestinal peptides and metabolites can help us
to understand the mechanism by which ingredients may
affect food consumption and energy balance. Ghrelin is
the first hormone to act in the appetite processes. It is
involved in the meal initiation and peak levels of ghrelin
are recorded just prior to food consumption [13]. Short-
term signals that are released during, or between, meals
include gastrointestinal (GI) peptides such as cholecysto-
kinin (CCK), glucagon-like peptide 1 (GLP-1), and pep-
tide tyrosine tyrosine (PYY) [14]. The gut hormone CCK
appears to be involved in satiation [14] and its experi-
mental administration reduces subsequent meal size[15]. However, CCK’s effect on suppressing food intake
is enhanced by stomach distension [16]. GLP-1 is a po-
tential biomarker for satiety [14]. When administered
experimentally to humans it can suppress energy intake,
promote satiety and decrease hunger [17,18]. There is
also evidence showing reduced GLP-1 levels in obese
subjects [19]. In addition, the administration of PYY, an-
other GI peptide affecting satiety, has been reported to
reduce food intake in humans [20]. CCK, GLP-1, and
PYY are released by the enteroendocrine I and L cells of
the small and large intestine in response to food intake,
i.e. during a meal [14,21]. However, the release of PYY
begins even before the nutrients reach the part of the
gut where it is produced [22]. These peptides are in-
volved with the process which helps to regulate the in-
testinal secretion and gut motility by transporting
signals to the brain which then reduce appetite [14,23].
Different foods have varying effects on postprandial me-
tabolism and more specifically on the secretion of gut pep-
tides [24]. Generally, fibers in food are able to enhance
satiety by adding bulk and viscosity [25]. They can also
alter the secretion of gut hormones and, thus, influence
metabolism and energy expenditure [26]. The impact of
different non-starch polysaccharides on satiety and sati-
ation have recently been reported [27]. In addition, previ-
ous studies on prebiotic fibers carried out on humans and
animals have shown that the consumption of lactitol [28]
and other highly fermentable fibers [29,30] is able to stimu-
late the secretion of GLP-1. On the other hand, increased
concentrations of plasma PYY have also been reported fol-
lowing the ingestion of lactitol [28] and inulin [31].
Polydextrose (PDX) is a randomly bonded, soluble and
branched glucose polymer with a high molecular weight
and low colonic fermentation rate [32,33]. PDX has been
recognized as soluble fiber and several studies have dem-
onstrated beneficial physiological effects associated with
this feature [34]. PDX is approved for use in foods in
over 60 nations and recognized as a dietary fiber in more
than 20 countries [35]. In addition, PDX is widely used
as a sugar and fat replacement in various food products
[36,37]. PDX has a low energy-density (4 kJ/g) and has
been shown to increase satiety and reduce energy intake
during a subsequent meal when administered as a sup-
plement 1.5 to 1 h before ad libitum lunch [38-41].
However, this effect was not significant when PDX was
given as a part of a breakfast meal [42,43]. PDX was re-
cently demonstrated to reduce the desire to eat and the
feeling of hunger when it replaced 30% of the other
available carbohydrates in the diet [44] equivalent to a
supplement of almost 50 g of PDX per day. But when
lower concentrations of PDX were used the results on
appetite ratings were not consistent [41,42,45]. However,
PDX can help maintain low postprandial blood glucose
levels [46].
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intake during a subsequent meal, its mechanism of ac-
tion is not yet fully understood. This study examines the
effects of a PDX-supplemented meal on appetite regula-
tion in obese participants. There are several studies
showing a reduction in appetite following the ingestion
of PDX as reported in both normal weight and over-
weight volunteers [39-41], however the data on obese par-
ticipants is lacking. The appetite suppressing mechanism
of PDX is hypothesized to function through satiety hor-
mones. Since satiety can also be linked to intestinal fer-
mentation [47,48], the postprandial plasma concentrations
of lactate and SCFAs were also evaluated.
Methods
Participants
The protocol was approved by the Research Ethics
Committee from the Hospital District of Northern Savo
in Finland (123/2007). The study was conducted in
2008 in two Finnish research centers located in Kuopio
and Vierumäki following the guidelines laid down by
the Declaration of Helsinki. The purpose of the study
was explained to all participants who gave their written
informed consent to be included in the study.
The inclusion criteria for participants were as follows:
age between 20 to 55 years old, body mass index (BMI)
between 30 to 37 kg/m2, and non-diabetic. In addition,
PDX is considered to be a dietary fiber [34]; hence the
participants had to have adapted a diet with moderately
low fiber content (typical fiber intake of less than 19 g/day
for men and 17 g/day for women). Participants were ex-
cluded if they presented any critical illness, inflammatory
bowel disease, celiac disease or malignancy in the GI track,
pregnancy, cardiovascular or metabolic diseases, or if they
were using any lipid lowering medication affecting serum
triglyceride concentrations, anti-obesity drugs or dietary
supplements with a high fiber content. Furthermore, the
regular (daily) use of fiber supplements, bran or seeds as
well as the regular and abundant use of non-steroidal anti-
inflammatory drugs was not allowed. In addition, persons
with familial hyperlipidemia were excluded from the study.
A structured interview focusing on previous and current
diseases, current medication, and alcohol and tobacco
consumption was carried out during a screening process
to clarify the health status and suitability of the partici-
pants. Body weight and height were also measured and
fasting blood samples were taken during this screening
process.
Study design
An acute, standardized, postprandial, randomized,
double-blind, placebo-controlled, cross-over (10 days
wash-out) and multicenter study using a high-fat meal
(4293 kJ, 36% from fat) was conducted on 18 volunteersaccording to a similar protocol as described earlier by
Ahotupa et al. [49]. The primary outcome of this study
was to determine any postprandial changes in serum tri-
glycerides (Tiihonen et al., unpublished observations).
The secondary outcomes assessed and reported in this
article were the effects of polydextrose on the satiety
hormone levels and subjective feelings of appetite using
VAS scores.
The participants included in this acute study were se-
lected from a related 4-week intervention study (not re-
ported here). Each participant was examined on two
separate occasions. Their body weight and height were
determined during the initial screening. The participants
were asked not to alter their medication, lifestyle or
body weight during the study and were advised to avoid
strenuous exercise and not to consume alcohol for 24 h
before the test days, nor to eat any items rich in fat on
the day before the test days. Participants’ use of
nicotine-containing products was noted from 24 h prior
to the start of the study. They were allowed to consume
up to 10 cigarettes (or equivalent) per day. Participants
also recorded their dietary intake from 3 p.m. the day
before the first postprandial test day and were asked to
adhere to this diet prior to the second postprandial test
to ensure a standardized meal load for both sessions.
After a 10 to 12 h fasting period on the study day, a
high-fat meal was provided to the participants in a ran-
domized order. The intervention meals were served at 10
a.m. and the last blood samples were taken at 4.30 p.m.
Participants were asked to eat the meal in 20 minutes and
they were not allowed to consume any additional food
during the 6 h testing period, except for water. Partici-
pants spent the study days in the laboratory and all phys-
ical exercise was forbidden during that time.
Composition of the study meal
The study meal consisted of a standard commercial
hamburger, french-fries and a carbonated drink. The en-
ergy and nutrient content of the study meal is presented
in Table 1. The experimental meals contained either 15
g of PDX (Litesse® Ultra™, DuPont) or not (placebo) in-
corporated into the drink. The amount of PDX used in
this study was aligned with the effective doses reported
in previous clinical trials [39,41]. The placebo drink con-
tained no additional ingredients. The addition of PDX
to the test drink increased the energy content of the
meal only by 60 kJ. A previous blind sensory test en-
sured that PDX did not change the appearance or taste
of the drink.
The meal termination time was the point at which the
whole meal had been consumed. Two hundred mL of
water was served to the participants two and four hours
after the meal. Additional spices were not allowed dur-
ing the meal.
Table 1 The energy and nutrient content of the study meals in placebo and PDX groups [50]
Weight (g)/volume (mL) Energy (kJ) Protein (g) Carbohydrates (g) Fat (g) Fiber (g) Salt (g)
Hamburger
Both groups 219 2071 27 40 (incl. 8 g sugar) 25 (SFAs 10 g) 3 2.3
French fries
Both groups 114 1423 5 42 (incl. 1 g sugar) 17 (SFAs 3 g) 4 0.4
Carbonated drink
Placebo group 450 799 < 0.1 42 < 0.1 0 0
PDX group 450 799 < 0.1 42 < 0.1 15 0
Total
Placebo group 783 4293 32 124 42 7 2.7
PDX group 783 4353 32 124 42 22 2.7
PDX, polydextrose; SFA, saturated fatty acid.
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Fasting blood samples used to analyze the lipid profile,
plasma glucose and serum insulin concentrations were
taken during the initial screening. To determine the con-
centration of ghrelin, CCK, GLP-1, PYY, SCFAs and lac-
tate, venous blood samples (10 mL) were taken through
a cannula inserted in a forearm vein twice before the
meal (0-sample), and 60, 120, 240 and 360 minutes after
the beginning of the meal during both study periods. A
baseline was set up with two measurements (0-samples)
taken within 10 minutes of each other. Serum was sepa-
rated by centrifugation (3000 rpm, 10 to 15 min) after
which it was stored at –70°C until analyzed. Plasma
samples were frozen at –70°C until analyzed.
The total plasma cholesterol content was analyzed
using an enzymatic, photometric method. High and low
density lipoprotein (HDL and LDL, respectively) choles-
terols were analyzed by direct measurement and the
total triglyceride concentrations were analyzed by en-
zymatic colorimetric assay using an automatic analyzer
(Roche/Hitachi MODULAR ANALYTICS, Roche Diag-
nostics GmbH, Mannheim, Germany) and commercial
reagents (cholesterol CHOD-PAP, Cat. No. 11875540;
HDL-cholesterol, Cat. No. 04713214; LDL-cholesterol, Cat.
No. 03038777; triglycerides, GPO-PAP, Cat. No. 11730711,
Roche Diagnostics GmbH, Mannheim, Germany). The
plasma LDL-cholesterol concentration was calculated
using the Friedewald formula [51]. Plasma glucose con-
centrations were analyzed using the hexokinase method
with citrate-fluoride. The serum insulin concentrations
were determined using an immunoluminometric assay
measured with an Immulite 2000 Analyzer (Thermo
Fisher Scientific Inc.).
The GI peptide (ghrelin, CCK, GLP-1, and PYY) con-
centrations in the plasma samples were analyzed by com-
petitive enzyme immunoassays (Phoenix Pharmaceutical,
Burlingame, CA, USA) according to the assays’ manufac-
turer’s instructions.Plasma SCFAs (acetic acid, propionic acid, butyric
acid, isobutyric acid, valeric acid, isovaleric acid, and 2-
methylbutyric acid) and lactic acid were analyzed by gas
chromatography as follows: internal standard (25 μL
20 mM pivalic acid) and 1.5 mL of acetonitrile were
added to 0.5 mL of the plasma sample. The sample was
then mixed thoroughly and centrifuged at 16000 × g for
3 min. The supernatant was then transferred to a 2 mL
centrifuge tube and 25 μL of 0.2 M NaOH was added. After
mixing, the sample was heated in a vacuum centrifuge at
60°C until dry. The residue was re-dissolved in 100 μL of
saturated oxalic acid–water solution (37:63). Then, 1 μL of
the sample solution was analyzed by gas chromatography
using a glass column packed with 80/120 Carbopack B-
DA/4% Carbowax 20 M stationary phase (2 m × 2 mm,
Supelco, Bellefonte PA, USA) at 175°C and using helium as
the carrier gas at flow rate of 24 mL/min. The
temperature of the injector and the flame ionization de-
tector were 200°C and 245°C, respectively.
Appetite ratings
Participants reported their subjective feelings of appetite
at time-point 0 (prior to the consumption of the meal)
and 40, 70, 140 and 280 minutes after the initiation of
the study meal. They rated their appetite feelings using
100 mm visual analogue scales (VAS) anchored at both
extremes, which were presented in paper form. Three
appetite ratings were evaluated in the study: hunger
(How hungry do you feel at the moment? I am not at all
hungry – I am very hungry), satisfaction (How satisfied
do you feel at the moment? I do not feel satisfied at all –
I feel very satisfied), and desire to eat (How strong is your
desire to eat at the moment? I do not have desire to eat
at all – My desire to eat is very strong). These questions
were adapted from [52] and [53]. The participants made
a vertical mark between the two extremities at the place
corresponding to what they were feeling at the exact
moment when the VAS was presented. The scores for




Age (years) 42.0 (26–53)
Weight (kg) 94.8 (73–114)
BMI (kg/m2) 33.6 (30–37)
Glucose (mmol/L) 5.65 ± 0.58
Insulin (mU/L) 9.75 ± 6.81
Triglycerides (mmol/L) 1.71 ± 0.96
Total cholesterol (mmol/L) 5.28 ± 1.19
LDL-cholesterol (mmol/L) 3.12 ± 0.96
HDL-cholesterol (mmol/L) 1.43 ± 0.51
Values are expressed as ratios*, mean values with their ranges (min–max) or
standard deviations (±SD).
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein.
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The similarity of the groups for the continuous-valued
parameters was assessed using the Student’s t test (nor-
mally distributed parameters) or Mann-Whitney U test
(other parameters). For the discrete-valued gender par-
ameter, Fisher’s exact test was used.
GI peptides, SCFAs and lactate
The results showing GI peptide, SCFA and lactate con-
centrations are presented here using an exploratory stat-
istical model. The concentrations were modeled using a
linear mixed-effects model which had fixed effect terms
for treatment, time point and interaction between treat-
ment and time point, as well as covariates for baseline
value, gender, BMI and age - i.e. the models were adjusted
for these factors. In addition, each model had a random ef-
fect, which is a subject-wise intercept term that takes into
account the fact that a setting with repeated measures per
subject was used. Post-hoc comparisons for GI peptides
and lactic acid were carried out for statistically significant
model terms of interest, e.g. age, BMI, or treatment. The
comparisons were carried out using model contrasts and
if multiple hypotheses were tested, the p values were ad-
justed to avoid false positives. If the model terms of inter-
est of BMI and age were significant, further post-hoc
analyses were conducted considering the following cut-off
values: BMI ≤ 34 kg/m2 and BMI > 34 kg/m2; and age ≤ 40 y
and age > 40 y.
Distribution of data values have been presented separ-
ately for each treatment and time point using box plots.
The whiskers represent minimum and maximum values
of the data (exceptionally large or small values outside
this range are shown using black dots). The box borders
indicate the 25% and 75% percentiles of the data and the
line inside the box is median of the data. As presented
in the figures, values in the y-axis are the original values
that have been subtracted from the treatment-wise me-
dian of values at time point 0. Vertical shifting of the
curves was done in order to ensure that their medians
are 0 at time point 0.
The linear mixed-effects model analyses were carried
out using R: A Language and Environment for Statistical
Computing ver. 3.01 [54]. The models were computed
using package nlme ver. 3.1 [55] and the contrasts were
computed using package multcomp ver. 1.2 [56].
Appetite ratings
Appetite ratings of hunger, satisfaction, and desire to eat
were divided into two periods, namely ‘satiation’ and‘satiety’, and expressed as incremental areas under the
curve (iAUC). To this end, appetite rating curves were ad-
justed to zero intensity at time point 40 min (post meal).
Thus, iAUC for satiation corresponds to the time points
starting immediately before the meal (0 min) and continu-
ing 40 minutes after the initiation of the meal; and iAUC
for satiety corresponds to the period between the
finalization of the meal (40 min) and the end of the appe-
tite ratings assessment (280 min). iAUC are reported as
mean ± SEM in min.mm. iAUC results for satiation and
satiety periods of each appetite rating for PDX or placebo
were compared using Student’s t tests (paired, two-tailed).
Sample size
Since the primary outcome of this clinical study was to de-
termine postprandial changes in serum triglycerides (not
reported here), the sample size was estimated according to
this parameter. Therefore, the sample size of 18 partici-
pants was calculated to be able to detect 86 mmol/L ×
min difference in iAUC for serum triglyceride concentra-
tion between the study periods with 80% power at α-level
of 0.05. The assumed standard deviation for iAUC for
serum triglyceride concentration was 130 mmol/L × min.
Equivalent sample sizes have been used in similar
study designs investigating changes in gastric peptides
[24,28,57,58].
Results
Characteristics of the study participants
Thirteen females and five males participated in the study.
The demographics and clinical characteristics of the partici-
pants are presented in Table 2. These parameters are refer-
ential values from the 4-week intervention that were taken
at screening. The mean BMI of study participants was 33.6
(min 30 – max 37) and the mean age 42 (±8) years. There
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kg/m2 and nine participants with a BMI higher than 34
kg/m2. With regards to age, seven participants were youn-
ger or 40 years old and eleven participants were older than
40 years. Although the participants were clinically obese,
their glucose and lipid metabolism appeared not to be sig-
nificantly disturbed. The average serum triglycerides were
slightly above the normal level and the total cholesterol
was at borderline of high risk according to the American
Heart Association’s guidelines [59]. However, the serum
concentrations of LDL and HDL-cholesterol were near
optimal or medium levels, respectively [59].
The population randomly selected into two arms was
homogenous, except for weight, which differed slightly
(P = 0.04) between the two populations. However, this
did not affect the results of this study, since weight gain
was not followed here. Additionally, there were no statis-
tical differences between the baseline values for satiety
peptides in the placebo and PDX groups.
Gastrointestinal peptides
The kinetic parameters of GI peptides are presented in
Table 3. Baseline values were statistically significant factors
(P < 0.0001) explaining the differences in the responses of
CCK, GLP-1, and PYY. Of all the GI peptides that were
monitored, only the secretion of GLP-1 was significantly
affected (P = 0.006) by the treatment effect; placebo vs.
PDX. In addition, GLP-1 and CCK concentrations were af-
fected by the time (P < 0.01). Furthermore, both age and
BMI significantly affected the concentration of GLP-1
(P = 0.02 and P = 0.04, respectively) and therefore a post-
hoc test was carried out. When these factors were taken
into consideration within a post-hoc multiple-hypothesis
test, it was observed that GLP-1 secretion into the plasma
increased significantly (P = 0.02) after the consumption of
PDX compared to the placebo (Figure 1C).
Because the model terms of interest of BMI and age
were statistically significant in the GLP-1 model, a further
post-hoc analysis was conducted with selected cut-off
values in the whole group. Results show that concentra-
tions of GLP-1 in participants older than 40 years old were
significantly lower (P = 0.01) as compared to those aged 40
years or less. However, there were no significant differ-
ences between participants with a BMI that was higher or
lower than 34 kg/m2 (P = 0.1).Table 3 Kinetic parameters of gastrointestinal peptides
Ghrelin CCK
Placebo PDX Placebo PD
Baseline (ng/mL) 0.41 ± 0.26 0.32 ± 0.17 0.33 ± 0.32 0.24 ±
Cmax (ng/mL) 0.54 ± 0.31 0.52 ± 0.35 0.8 ± 1.21 1.14 ±
Tmax (min) 100 ± 122 163 ± 160 120 ± 101 147 ±
Values are shown as means ± standard deviations.
CCK, cholecystokinin; GLP-1, glucagon-like peptide 1; PDX, polydextrose; PYY, peptiThere were no statistically significant differences in the
concentrations of ghrelin, CCK or PYY (Figure 1A,
B and D) between the placebo and the PDX test meals
when analyzed by a linear mixed-effects model. How-
ever, there was a tendency for the concentrations of
ghrelin and PYY to decrease after the consumption of
PDX, but the values did not reach statistically signifi-
cant levels due to a large standard deviation (P = 0.06
and P = 0.08, respectively).
Plasma SCFAs and lactic acid
The kinetic parameters of acetic acid and lactic acid are
presented in Table 4. The baseline values were statisti-
cally significant factors (P < 0.0001) which explain the
differences in the responses of acetic acid and lactic acid.
All other SCFAs were below detection limits. Acetate
and lactate exist in an ionized form within the usual
plasma pH range (7.35–7.45), thus they were analyzed in
the form of acetic acid and lactic acid.
A marginal 14.3% reduction in the concentration of
acetic acid after the consumption of PDX was observed
(P = 0.07) when analyzed by a linear mixed-effects model
(Figure 2A). The concentration of lactic acid was signifi-
cantly (P = 0.01) affected by the consumption of PDX
when compared to the control treatment. A linear
mixed-effects model with a post-hoc comparison for a
treatment effect shows that the concentration of lactic
acid decreased by 11.9% after the consumption of PDX
(Figure 2B). In addition, the time-point had a statistically
significant (P < 0.0001) effect on the differences in lactic
acid concentrations.
Appetite ratings
Results on appetite ratings are presented for hunger
(Figure 3), satisfaction (Figure 4), and the desire to eat
(Figure 5). There were no significant differences on the
satiation effects for the three appetite ratings tested
(Figures 3B, 4B and 5B). PDX significantly (P = 0.03) re-
duced hunger by 40.4% as compared to the placebo during
the satiety period (Figure 3C). In addition, PDX marginally
(P = 0.08) increased satisfaction by 22.5% as compared to
the placebo during the same period (Figure 4C). There
were no statistically significant differences on the subject-
ive feelings of desire to eat during the satiety period
(Figure 5C).GLP-1 PYY
X Placebo PDX Placebo PDX
0.15 130.8 ± 151.4 143.6 ± 218.4 0.43 ± 0.11 0.47 ± 0.14
1.64 212.7 ± 269.5 226.1 ± 229.6 0.53 ± 0.14 0.56 ± 0.19

































































Figure 1 Changes in the concentrations of gastrointestinal peptides in plasma. Changes in ghrelin (A), CCK (B), GLP-1 (C) and PYY (D) after
the ingestion of the study meal supplemented with the placebo or polydextrose (PDX) presented as box plots and analyzed by a linear mixed-effects
model. The GLP-1 response was increased significantly (P = 0.02) with PDX when compared to the placebo. The concentrations of ghrelin, CCK, and
PYY were not significantly altered by the treatments. The median of all values at the first time point (0 min) has been subtracted from the parameter
values presented in the box plots. CCK, cholecystokinin; GLP-1, glucagon-like peptide 1; PYY, peptide YY.
Table 4 Kinetic parameters of acetic acid and lactic acid
Acetic acid Lactic acid
Placebo PDX Placebo PDX
Baseline (mmol/L) 0.12 ± 0.1 0.16 ± 0.22 1.52 ± 0.44 1.79 ± 1.23
Cmax (mmol/L) 0.17 ± 0.14 0.17 ± 0.22 3.39 ± 1.35 3.32 ± 1.09
Tmax (min) 127 ± 142 80 ± 105 83 ± 72 67 ± 46
Values are shown as means ± standard deviations.
PDX, polydextrose.
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Dietary fibers are known to be associated with an en-
hanced satiety. However, the mechanism by which the
different dietary fibers contribute to the satiety-related
GI peptide release, especially in an obese population, is
still poorly understood. PDX shows similar beneficial
gastrointestinal functionalities as conventional grains










































Figure 2 Changes in the concentrations of acetic acid and lactic acid in plasma. Changes in postprandial acetic acid (A) and lactic acid
(B) in plasma after the ingestion of the study meal supplemented with the placebo or polydextrose (PDX) presented as box plots and analyzed
by a linear mixed-effects model. The decrease (11.9%) in the concentration of lactic acid after the consumption of PDX was statistically significant
when compared to the placebo (P = 0.01). The curves are adjusted to zero by subtracting the median of all values at the first time point (0 min)
from the parameter values presented in the box plots.
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http://www.nutritionj.com/content/14/1/2respect [34]. However, there are not enough data to con-
clude the effects of PDX on postprandial blood glucose
and fasting cholesterol levels [34]. As hypothesized in
this study, the potential for dietary PDX to affect the
postprandial metabolic parameters in obese subjects was
evaluated here with significant results in GLP-1 secre-
tion, plasma lactate concentration and the subjectiveTime (min)





































Figure 3 VAS results for the subjective feelings of hunger. A) The VAS
intensity at 40 min (after the meal). B) The incremental areas under the cur
between 0 min and 40 min (1176 ± 135 min.mm and 794 ± 179 min.mm, r
satiety period, i.e. between 40 min and 280 min, differed statistically (5487
visual analogue scales.feelings of hunger. The hypothesis was based on the ob-
servations found in the preliminary study conducted
with obese participants [60].
In this study, the obese - but otherwise healthy - partici-
pants consumed a typical western, moderately low fiber
diet. A high-fat hamburger meal was used as a model and

























curves of the placebo and polydextrose (PDX) adjusted to zero
ve (iAUC) for the placebo and PDX during the satiation period, i.e.
espectively, P > 0.05). C) The iAUC for the placebo and PDX during the





























































Figure 4 VAS results for the subjective feelings of satisfaction. A) The VAS curves of the placebo and polydextrose (PDX) adjusted to zero
intensity at 40 min (after the meal). B) The incremental areas under the curve (iAUC) for the placebo and PDX during the satiation period, i.e. between
0 min and 40 min (-1409 ± 95 min.mm and -1144 ± 143 min.mm, respectively, P > 0.05). C) The iAUC for the placebo and PDX during the satiety period,
i.e. between 40 min and 280 min (-6944 ± 1095 min.mm and -5385 ± 735 min.mm, respectively, P = 0.08). VAS, visual analogue scales.
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to a carbonated beverage consumed simultaneously with
the study meal. This presented a practical and efficient
way to increase the fiber content of a meal as well as to
study the postprandial effects of fiber-enrichment.
Different fermentable dietary fibers have previously
been reported to increase GLP-1 concentrations in ani-
mal studies [29,61,62], however similar results from hu-
man studies conducted with PDX had been few until
now, or reported in combination with other satiating
enhanced products [63]. In the present study, supple-
menting a high-fat meal with dietary PDX significantly
increased the concentration of postprandial plasma
GLP-1, when compared to the placebo. The GLP-1 re-
sponse 120 min after PDX supplementation correlates
kinetically with the intestinal fermentation pattern of






































Figure 5 VAS results for the subjective feelings of desire to eat. A) Th
intensity at 40 min (after the meal). B) The incremental areas under the curve
0 min and 40 min (1218 ± 134 min.mm and 1034 ± 153 min.mm, respectively
i.e. between 40 min and 280 min (6167 ± 1052 min.mm and 4939 ± 814 min.mimportant metabolic actions of GLP-1 are the stimula-
tion of insulin secretion and inhibition of glucagon se-
cretion; both of which are considered glucose-dependent
[65]. Native GLP-1 has a short half-life, but its longer-
acting analogues have been used successfully in the
treatment of obesity and T2D [65], and GLP-1 has been
shown to decrease blood glucose in human subjects with
T2D (reviewed in [66]). In the GI tract, GLP-1 can slow
down the postprandial gastric emptying rate and pro-
mote satiety through interactions with the gut and brain
[65]. Hence, the increased postprandial GLP-1 observed
in this study can present one mechanistic explanation
for the capability of PDX to increase satiety [39].
One of the most striking results of our study was to
find that age might also be an important factor in the
GLP-1 response. Here we report lower GLP-1 concen-























e VAS curves of the placebo and polydextrose (PDX) adjusted to zero
(iAUC) for the placebo and PDX during the satiation period, i.e. between
, P > 0.05). C) The iAUC for the placebo and PDX during the satiety period,
m, respectively, P > 0.05). VAS, visual analogue scales.
Olli et al. Nutrition Journal 2015, 14:2 Page 10 of 12
http://www.nutritionj.com/content/14/1/2compared to those aged 40 years or less in the whole
group of obese people. It is known that aging impairs in-
sulin sensitivity and reduces insulin and incretin produc-
tion [67]. In healthy subjects GLP-1 plays a key role in
the postprandial process which leads to the secretion of
insulin. However, this incretin effect is diminished in
subjects with T2D and those with impaired glucose tol-
erance. [68] Postprandial GLP-1 and PYY responses have
also been shown to be impaired in obese subjects com-
pared to those of normal weight [19,20].
The effect of PDX on postprandial ghrelin, CCK or
PYY release had not previously been reviewed in obese
subjects. However, Astbury et al. [63] have shown that
PDX is associated with higher GLP-1 and PYY responses
and with lower ghrelin responses in lean men. The
present study observed a trend in the decreasing levels
of ghrelin and PYY with PDX consumption; however,
the CCK concentration lacked any statistical significance
due to vast variations recorded with the measurements.
PYY is known to inhibit appetite and PDX has previ-
ously been demonstrated to increase acute satiety [39].
However, PYY also has other roles in appetite regulation
[23,69], and soluble fibers such as PDX do not necessar-
ily have a similar effect on all satiety-promoting pep-
tides. Endogenous ghrelin, on the other hand, stimulates
gastric motility and appetite [23]. A recent animal study
suggests that the SCFAs produced by colonic microbes
as a result of the fermentation of dietary fiber can also
cause L cells to trigger the release of GLP-1 and PYY
[70]. This may also influence appetite by sustaining sati-
ety after the meal and during the next meal.
It has been proposed that elevated triglyceride levels and
an elevated expression of appetite hormones are related
[71]. Obese individuals, in comparison to those of normal
weight, have important differences in their expression of
satiety hormones [14]. In fact, severely obese individuals
have higher levels of leptin and lower levels of adiponectin
[71] than those of normal weight. However, elevated levels
to leptin have less impact on satiety in obese subjects [72].
Meier et al. [73] have proposed that GLP-1 abolishes the
postprandial rise in triglyceride concentrations; therefore,
our findings indicating that PDX increases the level of
GLP-1 may be beneficial in reducing triglyceride lipids in
obese individuals following a high energy meal.
Given the findings of decreased postprandial plasma
lactate concentrations after the ingestion of the dietary sup-
plemented PDX, this study brings new insights into
obesity-linked postprandial metabolism. Obese subjects are
known to have high plasma lactate levels caused by the in-
creased lactate production in hypoxic adipose tissue [7,8].
Lactate has several metabolic roles; it functions as an en-
ergy source and as a metabolic product in the muscle dur-
ing intense exercise. It also induces insulin resistance in
muscle cells [74] and stimulates inflammation inmacrophages [75]. Lactate also modulates lipolysis in adi-
pocytes [76], mediating the anti-lipolytic action of insulin
[8,76]. However, in the obese state an increase in lactate
levels does not raise the anti-lipolytic effect of insulin
because of the loss of insulin sensitivity [8]. This study
shows the effect of dietary PDX on lower plasma lactate
levels after the consumption of a high-fat meal. A lipid-
containing meal is also reported to increase postprandial
endotoxemia [77], and other recent clinical trials have also
showed transient growth of circulating lipopolysaccharide
(LPS) levels after the consumption of energy-rich meals
(reviewed in [78]). In healthy humans the intravenous LPS
treatment has also been shown to raise lactate levels
within 90 minutes [79]. Both high-glucose and high-fat
meals are reported to induce postprandial inflammation,
while dietary fiber intake, in general, is associated with a
reduced, low-grade inflammation [3].
Statistically significant changes were noted in the ap-
petite ratings between the meals of this study, even
though the power calculation was carried out according
to the serum triglycerides (Tiihonen et al., unpublished
observations). In this study, PDX reduced hunger by
40.4% as compared to the placebo during the satiety
period. PDX also had a marginal effect on the feelings of
satisfaction increasing them by 22.5% as compared to the
placebo during the same period. Similar results have been
observed previously regarding hunger [39]. However, this
is the first time that this effect has been demonstrated
with obese individuals. In addition, PDX has been shown
to decrease energy intake in previous studies with normal
weight and overweight participants [39,40,63]. These ef-
fects, however, were observed when PDX was adminis-
tered as part of a mid-morning snack.
Conclusion
The present study demonstrates that PDX induces an en-
hanced GLP-1 response after the ingestion of a high-fat
meal by obese participants. GLP-1 secretion from the GI
tract is known to decrease gastric emptying and to con-
tribute to a decrease in food intake. PDX also induces a
lower postprandial plasma lactate concentration, which
can be associated with a lower post-meal inflammatory
status. In addition, age seemed to have an effect on GLP-1
response showing lower GLP-1 levels with older partici-
pants. Finally, this study shows that PDX can decrease the
subjective feelings of hunger. Thus, PDX may offer an
additional way of regulating inter-meal satiety and improv-
ing postprandial metabolism in obese subjects.
Abbreviations
BMI: Body mass index; CCK: Cholecystokinin; GI: Gastrointestinal; GLP-
1: Glucagon-like peptide 1; HDL: High density lipoprotein; iAUC: Incremental
area under the curve; LPS: Lipopolysaccharide; LDL: Low density lipoprotein;
PYY: Peptide tyrosine tyrosine; PDX: Polydextrose; SFA: Saturated fatty acid;
SCFA: Short chain fatty acid; SD: Standard deviation; SEM: Standard error of
the mean; T2D: Type 2 diabetes; VAS: Visual analogue scales.
Olli et al. Nutrition Journal 2015, 14:2 Page 11 of 12
http://www.nutritionj.com/content/14/1/2Competing interests
This work was funded by and the polydextrose provided by DuPont
Nutrition and Health. AI, KO, KS, KT, MS and NR are or have been employed
by a manufacturer of polydextrose (DuPont). The authors declare no other
conflict of interest regarding this study.Authors’ contributions
KT, NR and TV co-designed the study, which KT supervised. KO was responsible
for writing the manuscript. AI and KS participated in the manuscript and AI, KO,
KS, KT and MS all participated in the interpretation of the results. EA contributed
to the statistical analysis and data management and produced the box plot
images for this article. MS analyzed the plasma SCFA and lactate concentrations
and contributed to the manuscript. All authors have read and approved the
final version of the manuscript.Acknowledgements
Tarja Niskanen, Niina Tapola, Henna Karvonen and Essi Sarkkinen from
Foodfiles CRO are thanked for their contribution in the human clinical trial
and for writing the clinical trial report. Lauri Naski and David Bishop (DuPont
Nutrition and Health) are thanked for image preparation and proofreading of
the manuscript, respectively.
Author details
1DuPont Nutrition and Health, Active Nutrition, Sokeritehtaantie 20, FI-02460
Kantvik, Finland. 2Avoltus Oy, Turku, Finland. 3UKK Institute for Health
Promotion Research, Tampere, Finland. 4Danisco Health and Nutrition,
Kantvik, Finland.
Received: 18 June 2014 Accepted: 23 December 2014
Published: 3 January 2015References
1. Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling
role of white adipose tissue. Arch Physiol Biochem. 2008;114:267–76.
2. Holmer-Jensen J, Karhu T, Mortensen LS, Pedersen SB, Herzig KH,
Hermansen K. Differential effects of dietary protein sources on postprandial
low-grade inflammation after a single high fat meal in obese non-diabetic
subjects. Nutr J. 2011;10:115.
3. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, et al.
Dietary factors and low-grade inflammation in relation to overweight and
obesity. Br J Nutr. 2011;106 Suppl 3:5–78.
4. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and
potential targets. Nutrients. 2013;5:1218–40.
5. Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and
cardiovascular disease: current and future therapies. Curr Atheroscler Rep.
2013;15:309.
6. Blaak EE, Antoine JM, Benton D, Bjorck I, Bozzetto L, Brouns F, et al. Impact
of postprandial glycaemia on health and prevention of disease. Obes Rev.
2012;13:923–84.
7. DiGirolamo M, Newby FD, Lovejoy J. Lactate production in adipose tissue: a
regulated function with extra-adipose implications. FASEB J. 1992;6:2405–12.
8. Rooney K, Trayhurn P. Lactate and the GPR81 receptor in metabolic
regulation: implications for adipose tissue function and fatty acid utilisation
by muscle during exercise. Br J Nutr. 2011;106:1310–6.
9. Benelam B. Satiation, satiety and their effects on eating behaviour. Nutr Bull.
2009;34:126–73.
10. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, et al.
Appetite control: methodological aspects of the evaluation of foods.
Obes Rev. 2010;11:251–70.
11. de Lartigue G, de La Serre CB, Raybould HE. Vagal afferent neurons in high
fat diet-induced obesity; intestinal microflora, gut inflammation and
cholecystokinin. Physiol Behav. 2011;105:100–5.
12. Dockray GJ. Cholecystokinin. Curr Opin Endocrinol Diabetes Obes.
2012;19:8–12.
13. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A
preprandial rise in plasma ghrelin levels suggests a role in meal initiation in
humans. Diabetes. 2001;50:1714–9.
14. de Graaf C, Blom WAM, Smeets PAM, Stafleu A, Hendriks HFJ. Biomarkers of
satiation and satiety. Am J Clin Nutr. 2004;79:946–61.15. Muurahainen N, Kissileff HR, Derogatis AJ, Xavier Pi-Sunyer F. Effects of
cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in
man. Physiol Behav. 1988;44:645–9.
16. Kissileff HR, Carretta JC, Geliebter A, Pi-Sunyer FX. Cholecystokinin and
stomach distension combine to reduce food intake in humans. Am J Physiol
Regul Integr Comp Physiol. 2003;285:R992–8.
17. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety
and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.
18. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy
intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in
obese men. Int J Obes. 1999;23:304–11.
19. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated
GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916–9.
20. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, et al.
Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J
Med. 2003;349:941–8.
21. Karhunen LJ, Juvonen KR, Huotari A, Purhonen AK, Herzig KH. Effect of
protein, fat, carbohydrate and fibre on gastrointestinal peptide release in
humans. Regul Pept. 2008;149:70–8.
22. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, Rozé C. Mechanisms
of peptide YY release induced by an intraduodenal meal in rats:
Neural regulation by proximal gut. Pflugers Arch. 1997;433:571–9.
23. Halford JCG, Harrold JA. Satiety-enhancing products for appetite control:
science and regulation of functional foods for weight management.
Proc Nutr Soc. 2012;71:350–62.
24. Karhunen LJ, Juvonen KR, Flander SM, Liukkonen KH, Lahteenmaki L, Siloaho
M, et al. A psyllium fiber-enriched meal strongly attenuates postprandial
gastrointestinal peptide release in healthy young adults. J Nutr.
2010;140:737–44.
25. Slavin J, Green H. Dietary fibre and satiety. Nutr Bull. 2007;32 Suppl 1:32–42.
26. Sanchez D, Miguel M, Aleixandre A. Dietary fiber, gut peptides, and
adipocytokines. J Med Food. 2012;15:223–30.
27. Kumar V, Sinha AK, Makkar HPS, de Boeck G, Becker K. Dietary roles of
non-starch polysaccharides in human nutrition: a review. Crit Rev Food Sci
Nutr. 2012;52:899–935.
28. Gee JM, Johnson IT. Dietary lactitol fermentation increases circulating peptide
YY and glucagon-like peptide-1 in rats and humans. Nutrition. 2005;21:1036–43.
29. Massimino SP, McBurney MI, Field CJ, Thomson ABR, Keelan M, Hayek MG,
et al. Fermentable dietary fiber increases GLP-1 secretion and improves
glucose homeostasis despite increased intestinal glucose transport capacity
in healthy dogs. J Nutr. 1998;128:1786–93.
30. Cani PD, Neyrinck AM, Maton N, Delzenne NM. Oligofructose promotes
satiety in rats fed a high-fat diet: Involvement of glucagon-like peptide-1.
Obes Res. 2005;13:1000–7.
31. Lesniewska V, Rowland I, Cani PD, Neyrinck AM, Delzenne NM, Naughton PJ.
Effect on components of the intestinal microflora and plasma neuropeptide
levels of feeding Lactobacillus delbrueckii, Bifidobacterium lactis, and inulin
to adult and elderly rats. Appl Environ Microbiol. 2006;72:6533–8.
32. Flood MT, Auerbach MH, Craig SAS. A review of the clinical toleration
studies of polydextrose in food. Food Chem Toxicol. 2004;42:1531–42.
33. Fava F, Makivuokko H, Siljander-Rasi H, Putaala H, Tiihonen K, Stowell J, et al.
Effect of polydextrose on intestinal microbes and immune functions in pigs.
Br J Nutr. 2007;98:123–33.
34. Raninen K, Lappi J, Mykkanen H, Poutanen K. Dietary fiber type reflects
physiological functionality: comparison of grain fiber, inulin, and
polydextrose. Nutr Rev. 2011;69:9–21.
35. FAO/WHO. Codex alimentarius commission. In: Report of the 30th Session
of the Codex Committee on Nutrition and Foods for Special Dietary Uses,
vol. ALINORM 09/32/26. Joint FAO/WHO Food Standards Programme; 2009.
36. Lahtinen SJ, Knoblock K, Drakoularakou A, Jacob M, Stowell J, Gibson GR,
et al. Effect of molecule branching and glycosidic linkage on the
degradation of polydextrose by gut microbiota. Biosci Biotechnol Biochem.
2010;74:2016–21.
37. Craig SAS, Holden JF, Troup JP, Auerbach MH, Frier HI. Polydextrose as soluble
fiber: Physiological and analytical aspects. Cereal Foods World. 1998;43:370–6.
38. Auerbach MH, Craig SA, Howlett JF, Hayes KC. Caloric availability of
polydextrose. Nutr Rev. 2007;65:544–9.
39. Hull S, Re R, Tiihonen K, Viscione L, Wickham M. Consuming polydextrose in
a mid-morning snack increases acute satiety measurements and reduces
subsequent energy intake at lunch in healthy human subjects. Appetite.
2012;59:706–12.
Olli et al. Nutrition Journal 2015, 14:2 Page 12 of 12
http://www.nutritionj.com/content/14/1/240. Ranawana V, Muller A, Henry CJ. Polydextrose: its impact on short-term food
intake and subjective feelings of satiety in males–a randomized controlled
cross-over study. Eur J Nutr. 2013;52:885–93.
41. Astbury NM, Taylor MA, Macdonald IA. Polydextrose results in a dose-
dependent reduction in ad libitum energy intake at a subsequent test meal.
Br J Nutr. 2013;110:934–42.
42. Schwab U, Louheranta A, Torronen A, Uusitupa M. Impact of sugar beet
pectin and polydextrose on fasting and postprandial glycemia and fasting
concentrations of serum total and lipoprotein lipids in middle-aged subjects
with abnormal glucose metabolism. Eur J Clin Nutr. 2006;60:1073–80.
43. Monsivais P, Carter BE, Christiansen M, Perrigue MM, Drewnowski A. Soluble
fiber dextrin enhances the satiating power of beverages. Appetite.
2011;56:9–14.
44. Konings E, Schoffelen PF, Stegen J, Blaak EE. Effect of polydextrose and
soluble maize fibre on energy metabolism, metabolic profile and appetite
control in overweight men and women. Br J Nutr. 2014;111:111–21.
45. King NA, Craig SA, Pepper T, Blundell JE. Evaluation of the independent and
combined effects of xylitol and polydextrose consumed as a snack on
hunger and energy intake over 10 d. Br J Nutr. 2005;93:911–5.
46. Jie Z, Bang-yao L, Ming-jie X, Hai-wei L, Zu-kang Z, Ting-song W, et al.
Studies on the effects of polydextrose intake on physiologic functions in
Chinese people. Am J Clin Nutr. 2000;72:1503–9.
47. Conterno L, Fava F, Viola R, Tuohy KM. Obesity and the gut microbiota:
does up-regulating colonic fermentation protect against obesity and
metabolic disease? Genes Nutr. 2011;6:241–60.
48. Putaala H, Makivuokko H, Tiihonen K, Rautonen N. Simulated colon fiber
metabolome regulates genes involved in cell cycle, apoptosis, and energy
metabolism in human colon cancer cells. Mol Cell Biochem. 2011;357:235–45.
49. Ahotupa M, Suomela J-P, Vuorimaa T, Vasankari T. Lipoprotein-specific
transport of circulating lipid peroxides. Ann Med. 2010;42:521–9.
50. Fineli ® - Finnish Food Composition Database. [http://www.fineli.fi/]
[cited December 20, 2013].
51. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
52. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of
visual analogue scales in assessment of appetite sensations in single test
meal studies. Int J Obes Relat Metab Disord. 2000;24:38–48.
53. Hill AJ, Magson LD, Blundell JE. Hunger and palatability: Tracking ratings of
subjective experience before, during and after the consumption of
preferred and less preferred food. Appetite. 1984;5:361–71.
54. R Core Team. R: a language and environment for statistical computing. R
Foundation for Statistical Computing; [http://www.R-project.org/]
[cited November 1, 2013].
55. Pinheiro J, Bates D, Saikat D, Deepayan S, Team RDC. nlme: linear and
nonlinear mixed effects models. R package version 3.1-109. [database on
the Internet] [cited November 1, 2013].
56. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric
models. Biom J. 2008;50:346–63.
57. Hartvigsen ML, Gregersen S, Laerke HN, Holst JJ, Knudsen KEB, Hermansen K.
Effects of concentrated arabinoxylan and beta-glucan compared with refined
wheat and whole grain rye on glucose and appetite in subjects with the
metabolic syndrome: a randomized study. Eur J Clin Nutr. 2014;68:84–90.
58. Stringer DM, Taylor CG, Appah P, Blewett H, Zahradka P. Consumption of
buckwheat modulates the post-prandial response of selected gastrointestinal
satiety hormones in individuals with type 2 diabetes mellitus. Metabolism.
2013;62:1021–31.
59. Third Report of the National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143.
60. Tiihonen K, Ouwehand AC, Rautonen N. Effect of overweight on
gastrointestinal microbiology and immunology: correlation with blood
biomarkers. Br J Nutr. 2010;103:1070–8.
61. Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, et al.
Dietary resistant starch upregulates total GLP-1 and PYY in a sustained
day-long manner through fermentation in rodents. Am J Physiol Endocrinol
Metab. 2008;295:E1160–6.
62. Reimer RA, Maurer AD, Eller LK, Hallam MC, Shaykhutdinov R, Vogel HJ, et al.
Satiety hormone and metabolomic response to an intermittent high energy
diet differs in rats consuming long-term diets high in protein or prebiotic
fiber. J Proteome Res. 2012;11:4065–74.63. Astbury NM, Taylor MA, French SJ, Macdonald IA. Snacks containing whey
protein and polydextrose induce a sustained reduction in daily energy intake
over 2 wk under free-living conditions. Am J Clin Nutr. 2014;99:1131–40.
64. Kondo T, Nakae Y. Breath hydrogen and methane excretion produced by
commercial beverages containing dietary fiber. J Gastroenterol.
1996;31:654–8.
65. Gallwitz B. Anorexigenic effects of GLP-1 and its analogues. In: Joost HG,
editor. Appetite control: handbook of experimental pharmacology.
Volume 209. Berlin: Springer-Verlag; 2012. p. 185–207.
66. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.
67. Geloneze B, de Oliveira MS, Vasques ACJ, Novaes FS, Pareja JC, Tambascia
MA. Impaired incretin secretion and pancreatic dysfunction with older age
and diabetes. Metabolism. 2014;63:922–9.
68. Herzberg-Schafer S, Heni M, Stefan N, Haring HU, Fritsche A. Impairment of
GLP1-induced insulin secretion: role of genetic background, insulin resistance
and hyperglycaemia. Diabetes Obes Metab. 2012;14 Suppl 3:85–90.
69. Karra E, Chandarana K, Batterham RL. The role of peptide YY in appetite
regulation and obesity. J Physiol. 2009;587:19–25.
70. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al.
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the
G-protein-coupled receptor FFAR2. Diabetes. 2012;61:364–71.
71. Carlson JJ, Turpin AA, Wiebke G, Hunt SC, Adams TD. Pre- and post-prandial
appetite hormone levels in normal weight and severely obese women.
Nutr Metab. 2009;6:32.
72. Williams LM. Hypothalamic dysfunction in obesity. Proc Nutr Soc.
2012;71:521–33.
73. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, et al.
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride
concentrations and lowers levels of non-esterified fatty acids in humans.
Diabetologia. 2006;49:452–8.
74. Choi CS, Kim Y-B, Lee FN, Zabolotny JM, Kahn BB, Youn JH. Lactate induces
insulin resistance in skeletal muscle by suppressing glycolysis and impairing
insulin signaling. Am J Physiol Endocrinol Metab. 2002;283:E233–40.
75. Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive
transcription factor network in L6 cells: activation of MCT1 and
mitochondrial biogenesis. FASEB J. 2007;21:2602–12.
76. Liu C, Wu J, Zhu J, Kuei C, Yu J, Shelton J, et al. Lactate inhibits lipolysis in
fat cells through activation of an orphan G-protein-coupled receptor,
GPR81. J Biol Chem. 2009;284:2811–22.
77. Laugerette F, Vors C, Géloën A, Chauvin MA, Soulage C, Lambert-Porcheron
S, et al. Emulsified lipids increase endotoxemia: possible role in early
postprandial low-grade inflammation. J Nutr Biochem. 2011;22:53–9.
78. Kelly CJ, Colgan SP, Frank DN. Of microbes and meals: the health
consequences of dietary endotoxemia. Nutr Clin Pract. 2012;27:215–25.
79. Wellhoener P, Vietheer A, Sayk F, Schaaf B, Lehnert H, Dodt C. Metabolic
alterations in adipose tissue during the early phase of experimental
endotoxemia in humans. Horm Metab Res. 2011;43:754–9.
doi:10.1186/1475-2891-14-2
Cite this article as: Olli et al.: Postprandial effects of polydextrose on
satiety hormone responses and subjective feelings of appetite in obese
participants. Nutrition Journal 2015 14:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
